Preoperative HAIC enlarges future liver remnant in initial unresectable HCC patients with Vp3 tumor thrombus.
- 1Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- 2Department of Internal Medicine III, University Hospital Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany.
- 3Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Abstract
Background
Conversion strategy is the optimal treatment for patients with unresectable hepatocellular carcinoma (uHCC). However, a severe lack of future liver remnant (FLR) may result in early withdrawal. In this small sample retrospective study, we investigated FLR changes after conversion therapies. Notably, patients with ipsilateral Vp3 portal vein tumor thrombus (PVTT) showed a significant FLR increase after treatment and provided an advantage for carrying out radical surgery.Methods
53 uHCC patients with Vp0 to Vp3 tumor thrombus were enrolled and divided into two groups (Vp0-2 and Vp3) based on the initial PVTT status. All patients received anti-PD-L1 and anti-VEGF therapy combined with hepatic arterial infusion chemotherapy (HAIC) every three weeks. The FLR was measured at baseline and after 3-4 cycles. The odds ratio (OR) between Vp3 and FLR changes was calculated.Results
Among the 53 patients, 28 achieved complete response (CR) or partial response (PR) after conversion treatment. FLR did not change in Vp0-2 group, regardless of the response. While a significant FLR increase was observed in Vp3 group, especially in patients with CR and PR. 10 cases of successfully converted Vp3 patients showed an average FLR enlargement of 18.5%.Conclusion
According to our study, Vp3 patients demonstrated greater FLR enlargement after conversion therapy combined with HAIC, probably due to the thrombus' restriction on blood flow to the tumor side liver. This observation may help to increase both the surgeons' and the uHCC patients' confidence in continuing treatment.
Related
- Dramatic and sustained regression of an inferior vena cava tumor thrombus in a patient with unresectable giant hepatocellular carcinoma following sequential systemic therapy: a case report and literature review
- Survival outcomes of radiotherapy in elderly patients with unresectable stage III hepatocellular carcinoma: a population-based retrospective cohort study
- Early antibiotic exposure, but not late exposure, negatively affects the clinical outcomes of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
- Influence of patients’ sex on radiomics-based predictions of lung artery thrombus
- EUS-PPG Measured Distal to the Thrombus: A Reliable Way to Detect the Pressure Gradient in Patients With Cirrhosis and Portal Vein Thrombosis.
BibTeX
@article{zhang2026preoperative,
title = {{Preoperative HAIC enlarges future liver remnant in initial unresectable HCC patients with Vp3 tumor thrombus.}},
author = {Yifan Zhang and Yiquan Lu and Yuchen Yang and Xinyi Luo and Nan Wang and Fengjie Hao and Weixia Li and Yongjun Chen and Junqing Wang},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1906245},
url = {https://europepmc.org/article/MED/42898269},
note = {CC BY},
}
RIS
TY - JOUR
TI - Preoperative HAIC enlarges future liver remnant in initial unresectable HCC patients with Vp3 tumor thrombus.
AU - Yifan Zhang
AU - Yiquan Lu
AU - Yuchen Yang
AU - Xinyi Luo
AU - Nan Wang
AU - Fengjie Hao
AU - Weixia Li
AU - Yongjun Chen
AU - Junqing Wang
PY - 2026
DA - 2026/10/05
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1906245
UR - https://europepmc.org/article/MED/42898269
AB - Background Conversion strategy is the optimal treatment for patients with unresectable hepatocellular carcinoma (uHCC). However, a severe lack of future liver remnant (FLR) may result in early withdrawal. In this small sample retrospective study, we investigated FLR changes after conversion therapies. Notably, patients with ipsilateral Vp3 portal vein tumor thrombus (PVTT) showed a significant FLR increase after treatment and provided an advantage for carrying out radical surgery.Methods 53 uHCC patients with Vp0 to Vp3 tumor thrombus were enrolled and divided into two groups (Vp0-2 and Vp3) based on the initial PVTT status. All patients received anti-PD-L1 and anti-VEGF therapy combined with hepatic arterial infusion chemotherapy (HAIC) every three weeks. The FLR was measured at baseline and after 3-4 cycles. The odds ratio (OR) between Vp3 and FLR changes was calculated.Results Among the 53 patients, 28 achieved complete response (CR) or partial response (PR) after conversion treatment. FLR did not change in Vp0-2 group, regardless of the response. While a significant FLR increase was observed in Vp3 group, especially in patients with CR and PR. 10 cases of successfully converted Vp3 patients showed an average FLR enlargement of 18.5%.Conclusion According to our study, Vp3 patients demonstrated greater FLR enlargement after conversion therapy combined with HAIC, probably due to the thrombus' restriction on blood flow to the tumor side liver. This observation may help to increase both the surgeons' and the uHCC patients' confidence in continuing treatment.
SN - 2234-943X
ER -